Sweet Proteins and Fermentation Advance Sugar Reduction, Impacting UK Formulations

Chicago, United States — 23 July 2026

Sweet proteins are rapidly emerging as a critical component in next-generation sugar reduction strategies, driven by advancements in precision fermentation and molecular agriculture. The IFT FIRST 2026 exhibition in Chicago highlighted how these technologies are enabling the scalable production of previously rare sweet proteins like thaumatin, brazzein, and novel discoveries such as MycoTechnology’s Zukora Honey Truffle Sweet Protein. This shift provides supplement and food manufacturers with new tools to replicate sugar's sensory performance.

MycoTechnology showcased its Zukora, an ingredient 2,000 times sweeter than sugar, derived from an obscure Hungarian truffle. The company secured self-GRAS status for Zukora in March 2026, demonstrating rapid commercialisation capabilities. Similarly, Spain-based Nambawan promoted Thaûma, a branded thaumatin II produced via recombinant technology and plant molecular farming, highlighting its potential as a 'universal co-sweetener' to mitigate off-notes from stevia and monk fruit. Despite the genetic modification of host plants, Nambawan asserts the final product can be labelled non-GMO, backed by four US FDA GRAS approvals and JECFA endorsement.

Alongside these innovative proteins, traditional high-intensity sweeteners are undergoing significant evolution. Layn Natural Ingredients introduced a gently extracted monk fruit decoction, retaining more of the original fruit's profile with a sweetness potency of 4-5 times sugar. Crucially for the UK market, this decoction is not considered a novel food in Europe or the UK, streamlining regulatory pathways. Layn also unveiled Reb M2, a fully water-soluble steviol glycoside produced via enzymatic bioconversion, addressing previous formulation limitations for clear beverage applications. Manus, a US biotech company, is also pursuing precision fermentation for mogroside production, aiming to diversify monk fruit supply chains away from current Chinese dependencies, though US FDA clearance is still pending.

Synergistic blending remains a core strategy. Exhibitors like Ingredion and Nura demonstrated how sweet proteins, such as brazzein, are effectively combined with stevia or monk fruit to enhance taste profiles and reduce cost-in-use. These blends aim to overcome sensory challenges associated with single high-intensity sweeteners, offering more comprehensive sugar reduction solutions.

What this means for United Kingdom

UK supplement manufacturers and brand owners can leverage these emerging sweet proteins and enhanced sweetener formats to address increasing consumer demand for sugar reduction without compromising taste. The non-novel food status of Layn’s monk fruit decoction offers a faster market entry point, while water-soluble Reb M2 improves formulation flexibility for novel beverage and liquid supplement products. Manufacturers should explore blending strategies, particularly with stevia and the new sweet proteins, to achieve optimal sensory performance and cost-in-use benefits. Regulatory teams must monitor the MHRA and FSA stances on novel sweet proteins and fermentation-derived ingredients to ensure compliance, especially when considering imports from the US market where GRAS status may not directly translate.

The emphasis on 'sweet proteins' over 'sweeteners' also presents a marketing opportunity in the protein-conscious UK market, despite their minimal contribution to total protein content.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.